down arrow

Greenwich LifeSciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US3968791083
USD
8.80
0.8 (10.0%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

8.308.85

52 Week

7.7814.47
Valuation
Technical
Day's Volume

CASH

46.67 k

Shareholding (Mar 2025)

FII

2.81%

Held by 15 FIIs

DII

92.08%

Held by 5 DIIs

Promoter

0.00%

How big is Greenwich LifeSciences, Inc.?

22-Jun-2025

As of Jun 18, Greenwich LifeSciences, Inc. has a market capitalization of 120.72 million and reported net sales of 0.00 million with a net profit of -16.58 million for the latest four quarters. As of Dec'24, shareholder's funds were 2.53 million and total assets were 4.09 million.

Market Cap: As of Jun 18, Greenwich LifeSciences, Inc. has a market capitalization of 120.72 million, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in Mar'25, Dec'24, Sep'24, and Jun'24, the company reported net sales of 0.00 million and a net profit of -16.58 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company's shareholder's funds amounted to 2.53 million, while total assets were reported at 4.09 million.

Read More

What does Greenwich LifeSciences, Inc. do?

22-Jun-2025

Greenwich LifeSciences, Inc. is a clinical stage biopharmaceutical company focused on developing GP2, an immunotherapy aimed at preventing breast cancer recurrence post-surgery. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $120.72 million.

Overview: <BR>Greenwich LifeSciences, Inc. is a clinical stage biopharmaceutical company engaged in developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 120.72 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.10 <BR>Return on Equity: -1,262.96% <BR>Price to Book: 91.99<BR><BR>Contact Details: <BR>Address: 3992 Bluebonnet Dr, Building 14, STAFFORD TX : 77477 <BR>Tel: 1 203 4343290 <BR>Website: https://greenwichlifesciences.com

Read More

Who are in the management team of Greenwich LifeSciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Greenwich LifeSciences, Inc. includes David McWilliams (Independent Chairman), Snehal Patel (CEO, CFO, Director), F. Joseph Daugherty (Chief Medical Officer, Director), Kenneth Hallock (Independent Director), and Eric Rothe (Independent Director). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Greenwich LifeSciences, Inc. includes the following individuals:<BR><BR>- Mr. David McWilliams, who serves as the Independent Chairman of the Board.<BR>- Snehal Patel, who holds the positions of Chief Executive Officer, Chief Financial Officer, and Director.<BR>- Mr. F. Joseph Daugherty, who is the Chief Medical Officer and Director.<BR>- Kenneth Hallock, who is an Independent Director.<BR>- Mr. Eric Rothe, who is also an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Greenwich LifeSciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Greenwich LifeSciences, Inc. shows a mildly bullish trend, supported by bullish weekly MACD and moving averages, despite underperforming the S&P 500 over the past year.

As of 12 September 2025, the technical trend for Greenwich LifeSciences, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages are bullish, and the weekly Bollinger Bands also indicate a bullish stance. However, the monthly KST is bearish, and the Dow Theory shows a mildly bullish trend on a monthly basis with no trend on a weekly basis. <BR><BR>In terms of performance, the stock has returned -18.56% over the past year compared to a 17.14% return for the S&P 500, indicating underperformance, but it has a positive return of 2.76% year-to-date versus the S&P 500's 12.22%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish signals from the MACD and moving averages.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 152 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-2.17

stock-summary
Return on Equity

-1,249.93%

stock-summary
Price to Book

105.77

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.68%
0%
-23.68%
6 Months
-7.85%
0%
-7.85%
1 Year
-37.54%
0%
-37.54%
2 Years
-24.72%
0%
-24.72%
3 Years
-36.0%
0%
-36.0%
4 Years
-74.01%
0%
-74.01%
5 Years
57.09%
0%
57.09%

Greenwich LifeSciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Greenwich LifeSciences, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Greenwich LifeSciences, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages are bullish, and the weekly Bollinger Bands also indicate a bullish stance. However, the monthly KST is bearish, and the Dow Theory shows a mildly bullish trend on a monthly basis with no trend on a weekly basis. In terms of performance, the stock has returned -18.56% over the past year compared to a 17.14% return for the S&P 500, indicating underperformance, but it has a positive return of 2.76% year-to-date versus the S&P 500's 12.22%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish signals from the MACD and moving averages....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-274.54%
EBIT to Interest (avg)
-10.16
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.10
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.27%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
98.40
EV to EBIT
-7.54
EV to EBITDA
-7.54
EV to Capital Employed
-87.91
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-1262.96%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 9 Schemes (5.1%)

Foreign Institutions

Held by 15 Foreign Institutions (2.81%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -53.85% vs -62.50% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.00",
          "val2": "-2.70",
          "chgp": "-48.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.00",
          "val2": "-2.60",
          "chgp": "-53.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -77.53% vs -14.10% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.00",
          "val2": "-9.30",
          "chgp": "-72.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.80",
          "val2": "-8.90",
          "chgp": "-77.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.00
-2.70
-48.15%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.00
-2.60
-53.85%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -53.85% vs -62.50% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-16.00
-9.30
-72.04%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-15.80
-8.90
-77.53%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -77.53% vs -14.10% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Greenwich LifeSciences, Inc. stock-summary
stock-summary
Greenwich LifeSciences, Inc.
Pharmaceuticals & Biotechnology
Greenwich LifeSciences, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a nine amino acid transmembrane peptide of the human epidermal growth factor receptor two (HER2/neu) protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide specific immunity. Following GP2 immunotherapy, CD8+ cytotoxic T lymphocytes (TCL) recognizes and destroys HER2/neu-expressing cancer cells. The Company’s GP2 treatment is administered through an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The GM-CSF is available in both liquid and lyophilized forms.
Company Coordinates stock-summary
Company Details
3992 Bluebonnet Dr, Building 14 , STAFFORD TX : 77477
stock-summary
Tel: 1 203 4343290
stock-summary
https://greenwichlifesciences.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."